The fusion of mRNA technology with AI has laid the foundation for ushering in a new era of cancer care. However, conducting ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

The latest guidance reduction was the second time in the last six months that the firm has revised its forecast in a negative ...

Q&A: From people avoiding wild birds to farmers protecting their animals, Kent State epidemiologist Dr. Tara Smith shares ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

But that doesn’t mean an H5N1 avian influenza pandemic isn’t possible ... million to help accelerate the development of a bird flu vaccine. The agency announced its backing of the ...

mRNA vaccines offer clear advantages and disadvantages ... candidates for seasonal influenza and COVID-19 in Phase 2 and avian influenza in Phase 1 clinical development. Sanofi is developing ...

We recently compiled a list of the The 10 Worst-Performing Stocks on Monday. In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against the other stocks. Ten ...

The research evaluates the vaccine's immunogenicity and protective efficacy in both murine and avian models, seeking to establish a new paradigm for avian influenza vaccination strategies. The mRNA ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.